Search Result for : Drug Manufacturing

The Dollar Business Bureau Drug manufacturing company Aurobindo Pharma Ltd is planning to launch around 200 products in the European market in the coming four years in order to enhance the product portfolio of the company. “The next lever of growth will come from new products which are being developed. Currently, we have almost 200 products under development for Europe alone and that will be launched over next three to four years,” Sanjeev Dani, COO & Head Formulations, Aurobindo Pharma told analysts. That will be the growth driver in the Europe, he added. In the first quarter of the fiscal 2016-17, the formulations sales of the company in Europe stood at Rs.831.2 crore witnessing a growth of 12.1 percent year-on-year. In the segment of formulations, the EU market ...

The Dollar Business Bureau Suven Life Sciences (Suven) on Tuesday announced it has received approvals of one product patent each from India and South Africa.  “One product patent from India and one product patent from South Africa corresponding to the New Chemical Entities (NCEs) for treatment of disorders associated with neuro-degenerative diseases," the company said in an announcement.   These two patents are valid through 2028 and 2032 respectively. The granted patents include the class of 5-HT6 compounds and H3 inverse agonist compounds. There are being developed as therapeutic agents and will be used for the treatment of cognitive impairment related to neurodegenerative disorders such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, major depressive disorder (MDD), Parkinson and Schizophrenia. With the grants of ...

The Dollar Business Bureau Indian drug major Aurobindo Pharma, on Friday, got an approval from the United States Food and Drug Administration (USFDA) to manufacture and market drugs used in the long-term treatment of moderate-to-severe pain in adults. “The company has received final approval from the USFDA to manufacture and market Tramadol Hydrochloride Extended-release Tablets USP, 100 mg, 200 mg and 300 mg (ANDA 204421). This product will be launched by Q4 FY 2015-16,” said an official release. The approved product, having an estimated market size of $56 million for the twelve months ending August (according to IMS), is the 50th Abbreviated New Drug Application (ANDA-US generic drug approval for an existing licensed medication) to be approved at ‘formulation facility for ...

Himanshu Vatsa | The Dollar Business The government has extended the anti-dumping duty imposed on Vitamin E imports from China for another five years. A duty of up to $1.77 per kg of import will be levied on all forms of processed Vitamin E shipped in to India from China, the Customs Department said in a notification issued on Wednesday. However, the product in its natural form has been exempted from anti-dumping duty, the notification said. The Finance Ministry had imposed the duty on Chinese Vitamin E in March 2009 for five years and later extended till March 2015. The fresh notification came after the Directorate General of anti-dumping and Allied Duties (DGAD) found that Vitamin E in various forms was ...